The INDICAID™ COVID-19 Rapid Antigen Test (FDA EUA) is a lateral flow immunoassay designed for the qualitative detection of SARS-CoV-2 antigens in direct nasal swab samples.
Out of stock
The INDICAID™ COVID-19 Rapid Antigen Test is a lateral flow immunoassay designed for the objective identification of SARS-CoV-2 antigens. Antigen tests are designed to detect proteins from the virus that causes COVID-19 through swab specimens taken from a patient’s nose.
This point-of-care test kit is intended for use by healthcare professionals in symptomatic individuals within 5 days after onset of symptoms. This product has received FDA Emergency use authorization.
In a prospective US clinical study, INDICAID accurately indentified 84% of those who were positive (PPA) and 97% of those who were negative (NPA) for SARS-CoV-2. Product performance against variants of concern are evaluated on an ongoing basis.
INDICAID’s intuitive vial design allows for the aggregate collection of multiple specimens followed by batch-testing of individual samples up to two (2) hours after collection.